For cardiovascular protection, PPAR agonists (e.g., pioglitazone, fenofibrate) improve lipid profiles and reduce inflammation, while mineralocorticoid receptor antagonists (e.g., Eplerenone) help prevent heart failure [241]. Here, NR3C2 is linked to heart failure.